Emerging Therapies for SMA. Francesco Muntoni
|
|
- Dwayne Lambert
- 5 years ago
- Views:
Transcription
1 Emerging Therapies for SMA Francesco Muntoni TREAT-NMD Alliance Conference 2013 Newcastle Dubowitz Neuromuscular Centre UCL Institute of Child Health & Great Ormond Street Hospital London
2 Therapeutic targets for SMA example Mutation of smn1 Replacement of SMN1 Gene therapy Alternative splicing of smn2 Inclusion of exon 7 Antisense Pharmacological upregulation Diminution of fulllength smn transcript Increase of SMN transcripts HDAC inhibitors Hydroxyurea Quinazolones SMN protein deficit Stabilisation of SMN protein Indoprofen Proteasome inhibitors Polyphenols Loss of motorneurons Clinical symptoms Neuroprotection Cell therapy Riluzole, TRO19622 Neurotrophic factors Stem cells
3 SMN splicing DNA p44 NAIPΨ SMN2 SMN1 NAIP p44 Type I mrna % Fl.SMN % % Δ7.SMN Full length SMN protein SMA patients are depleted of full length SMN protein. The small amount of SMN protein in these patients derives from the inefficient inclusion of SMN exon 7 in SMN2 transcript (~10% of all transcript) Type III
4 Modifying SMN2 splicing With antisense oligonucleotides With pharmacological agents
5 ISIS-SMN Rx : Modulating Splicing of SMN2 to Increase Normal SMN Protein 5 Uniformly 2 -O-methoxyethyl modified (MOE) antisense drug Corrects the splicing disorder in SMN2, resulting in the production of fully functional SMN protein in model systems In mild and severe mouse models of SMA provides a phenotypic and pathological benefit when delivered centrally* Distributes broadly to spinal cord motor neurons after intrathecal delivery in monkeys* Has a long half life in CNS tissue (>6 months in animal models) HO O O S P O O O O B O O OCH 3 B OCH 3 SMN2 Gene SMN2 Gene C to T C to T 1 2 a 2b a 2b SMN2 mrna ISIS-SMN Rx SMN2 mrna Defective Protein, missing exon 7 Functional Protein *(Hua et al., Genes Dev., 2010; Passini et al., Sci Transl Med, 2011; Hua et al., Nature, 2011)
6 SMN Targeting ASO Preserves Neuron and Muscle Function in a Mouse Model of SMA SMN Targeting ASO Preserves Neuromuscular Junctions ISIS SMN Rx SMN Targeting ASO Maintains Muscle Fiber Size ISIS SMNRx ISIS SMN Rx 6
7 Clinical Program for ISIS-SMN Rx Orphan Drug Status in US and EU; Fast Track Designation in USA Phase 1 Single-dose Study in Children with SMA completed - ISIS-SMN Rx well tolerated, no safety concerns identified - Preliminary, but encouraging changes in HFMSE scores observed at highest dose Phase 1b/2a Multiple-dose Study in Children with SMA - ongoing Phase 2 Multiple-dose Study in Infants with SMA - ongoing Two pivotal, controlled studies planned to start in 2014, to be conducted worldwide, including Europe -Phase 2/3 study in Infants with SMA -Phase 2/3 study in Children with SMA
8 Phase 1 open label, single dose study in SMA II-III patients 2-14 years of age.
9 9 Long-term Follow-Up HFMSE Scores of Type 2/3 SMA Subjects in Single-dose Study (full study data at Mean + SEM At 9 to 14 months post-dose, mean change from baseline in HFSME = -1.7, 0.5, 2.5, and 5.75 for 1, 3, 6, and 9 mg groups respectively 9 mg group mean change from baseline = 5.75 points (p = 0.008), % change = 32.8%; no 9 mg subjects had declined (range = 1 to 14 point improvement)
10 Other antisense backbones Morpholino backbone chemistry is at least as effective than MOE, but direct ICV administration still required
11 Strategies to target AOs to the Central Nervous System a.incapsulate the AO with small particles b.link the AON directly to a targeting peptide c. use other modifications of backbone
12 B peptide MSP -GGCCAAACCTCGGCTTACCTGAAAT
13 Tricyclo-DNA Platform As LNA, tc-dna has been designed as a CONFORMATIONALLY CONSTRAINED oligonucleotide analogue. Chemical modifications change the properties of natural oligodeoxynucleotides by: Increased RNA AFFINITY by 2-4 C / modification; Increased HYDROPHOBICITY; Increased STABILITY towards nucleolytic degradation for both, phosphate or thiophosphate internucleoside linkages; Inability to elicit RNaseH activity. Unlike LNA, tc-oligonucleotides in the LENGTH RANGE OF nucleotides can easily be prepared and produce potent antisense effects. Courtesy of V. Robin
14 Pharmacological modification of SMN2 splicing In vitro activity of SMN2 splicing modifiers SMN protein increase in Type I SMA fibroblasts
15 Discovery/Optimization of Quinazolines for Potential Treatment of SMA SMN2 promoter assay-based HTS run by Aurora (subsequently Vertex) Jarecki et al. (2005) Hum. Mol. Genet. 14(14): N NH 2 Hit/Lead optimization by DeCODE Chemistry Inc. using promoter assay O N NH 2 Thurmond et al. (2008) J. Med. Chem. 51: N DcpS (scavenger decapping enzyme) identified as putative target of C5-substituted quinazolines by decode Chemistry Inc. Singh et al. (2008) ACS Chem. Biol. 3(11): F D Demonstration of increased Smn promoter activity in vivo in CNS of SMA mice by 2,4-diaminoquinazoline derivatives and increased in survival by D Butchbach et al. (2010) Hum. Mol. Genet. 19(3):
16 Discovery/Optimization of Quinazolines for Potential Treatment of SMA, continued 2009: Program licensed from Families of SMA to RepliGen RepliGen selects D (RG3039) as clinical lead 2011: RG3039 enters the clinic supported by a grant from Muscular Dystrophy Association Beneficial effects of RG3039 demonstrated in 3 different SMA mouse models Gogliotti et al. (2013) HMG. 22(20): Van Meerbeke et al. (2013) HMG. 22 (20) : Jan 2013: Announcement of program being licensed from RepliGen to Pfizer 16
17 Gene Therapy
18
19
20 A clinical trial of olesoxime (TRO19622) in SMA Trophos Study sites: 22 sites in France, Germany, Italy, UK, Poland, Netherlands, Belgium Total number of subjects: 150 patients in total, 100 in the olesoxime group, and 50 in the placebo group. Study duration: Total of 33 months with a 9 months recruitment period and a 2 years treatment period Outcome of the study expected 4Q2013
21 Acknowledgements Neuromuscular Translational Research Centre London and Newcastle
SMA Therapeutics: A Comparative Overview of Drugs Approved and in Development. Sponsored By:
SMA Therapeutics: A Comparative Overview of Drugs Approved and in Development Sponsored By: August 8, 2017 Targets for Therapeutic Intervention in SMA Decrease in SMN protein due to SMN1 gene deletion
More informationPanel II: SMA Drugs in Development
Panel II: SMA Drugs in Development Jinsy Andrews MD, Director of Clinical Research and Development, Cytokinetics Thomas Blaettler MD, Global Clinical Development Team Leader, F. Hoffmann-La Roche Jerry
More informationSMA IS A SEVERE NEUROLOGICAL DISORDER [1]
SMA OVERVIEW SMA IS A SEVERE NEUROLOGICAL DISORDER [1] Autosomal recessive genetic inheritance 1 in 50 people (approximately 6 million Americans) are carriers [2] 1 in 6,000 to 1 in 10,000 children born
More informationSpinal Muscular Atrophy as a Focus Indication for Biomarker Development. Meg Winberg, PhD Spinal Muscular Atrophy Foundation February 26, 2007
Spinal Muscular Atrophy as a Focus Indication for Biomarker Development Meg Winberg, PhD Spinal Muscular Atrophy Foundation February 26, 2007 Why SMA? p Low incidence, but a large orphan indication p Scientifically
More informationISIS-SMN Rx Background and Current Status. C. Frank Bennett Sr. VP, Research Isis Pharmaceuticals
ISIS-SMN Rx Background and Current Status C. Frank Bennett Sr. VP, Research Isis Pharmaceuticals ISIS-SMN Rx : Modulating Splicing of SMN2 to Increase Normal SMN Protein 2 Uniformly 2 -O-methoxyethyl modified
More informationSPINRAZA (NUSINERSEN)
SPINRAZA (NUSINERSEN) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0059D Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2018 10/2019 10/2018 Description of Procedure or Service Spinal muscular atrophy
More informationAngelman Syndrome: Research landscape. Ben Philpot, Ph.D., University of North Carolina Stormy Chamberlain, Ph.D., University of Connecticut
Angelman Syndrome: Research landscape Ben Philpot, Ph.D., University of North Carolina Stormy Chamberlain, Ph.D., University of Connecticut OUTLINE Research Biochemistry Mouse studies Other models Therapeutic
More informationSpinal Muscular Atrophy in 2017
Spinal Muscular Atrophy in 2017 Leigh Maria Ramos-Platt, MD Children s Hospital of Los Angeles University of Southern California Keck School of Medicine Disclosures MDA Care Center Grant In this presentation,
More informationISIS PHARMACEUTICALS. ISIS-SMN Rx Investor Event. March 21, Slides available for download at:
ISIS PHARMACEUTICALS ISIS-SMN Rx Investor Event March 21, 2013 Slides available for download at: http://www.isisph.com Forward Looking Language Statement 2 This presentation includes forward-looking statements
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy
More informationSpinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through
More information12th UK Neuromuscular Translational Research Conference Centre for Life, Newcastle
12th UK Neuromuscular Translational Research Conference Centre for Life, Newcastle Thursday 4 and Friday 5 April 2019 PROGRAMME Day 1 Thursday 4 April 09:00 09:30 Registration and Coffee 09:30 09:40 Introduction
More informationTREAT-NMD and the Role of the Industry in Orphan Diseases. Dr. Stefanie Possekel Santhera Pharmaceuticals
TREAT-NMD and the Role of the Industry in Orphan Diseases Dr. Stefanie Possekel Santhera Pharmaceuticals TREAT-NMD EU-funded infrastructure to accelerate therapy development in neuromuscular diseases Clinical
More informationSmall Molecules in Development for the Treatment of Spinal Muscular Atrophy
Small Molecules in Development for the Treatment of Spinal Muscular Atrophy Alyssa N. Calder, a Elliot J. Androphy, b Kevin J. Hodgetts a* a Laboratory for Drug Discovery in Neurodegeneration, Brigham
More informationFinal Phase 3 Study Data Show SPINRAZA (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
MEDIA CONTACT: Biogen Ligia Del Bianco Ph: +1 781 464 3260 public.affairs@biogen.com INVESTOR CONTACT: Biogen Ben Strain Ph: +1 781 464 2442 IR@biogen.com Final Phase 3 Study Data Show SPINRAZA (nusinersen)
More informationClinical Policy Bulletin: Nusinersen (Spinraza)
Clinical Policy Bulletin: Nusinersen (Spinraza) Number: 0915 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. Note: REQUIRES PRECERTIFICATION.Footnotes for Precertification of nusinersen
More informationObjectives. What is SMA? Pathophysiologic and genetic mechanisms How to identify a case of SMA
Objectives What is SMA? Pathophysiologic and genetic mechanisms How to identify a case of SMA What can be done? Review of advances in standards of care and treatment Detailed review of treatment available
More informationHow to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy
How to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy CTs in rare diseases London 30 th November 2015 Michela Guglieri JWMDRC Newcastle upon Tyne Michela.guglieri@Newcastle.ac.uk
More informationSpinraza (nusinersen)
Spinraza (nusinersen) Policy Number: 5.02.540 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Spinraza
More informationPrior Authorization Update: Nusinersen
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUpdate in Neuromuscular Disorders Tuesday 5- Friday 8 May Clinical Neuroscience Lecture Theatre at 33 Queen Square, London WC1N 3BG PROGRAMME
Update in Neuromuscular Disorders Tuesday 5- Friday 8 May 2015 Clinical Neuroscience Lecture Theatre at 33 Queen Square, London WC1N 3BG Day 1 Tuesday 5 May PROGRAMME 10:00 10:30 Registration* and coffee
More informationProgress and Promise: The Current Status of Spinal Muscular Atrophy Therapeutics
Discovery Medicine www.discoverymedicine.com ISSN: 1539-6509; eissn: 1944-7930 291 Progress and Promise: The Current Status of Spinal Muscular Atrophy Therapeutics JAmeS P. VAN meerbeke ANd ChArlotte J.
More informationTherapy development in spinal muscular atrophy
n e u r o d e g e n e r a t i o n p e r s p e c t i v e Therapy development in spinal muscular atrophy Michael Sendtner Proximal spinal muscular atrophy (SMA) is the predominant form of motor neuron disease
More information2018 F. Hoffmann-La Roche Ltd. All rights reserved.
PRELIMINARY EVIDENCE FOR PHARMACODYNAMIC EFFECTS OF RG7916 IN JEWELFISH A STUDY IN PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN A STUDY WITH ANOTHER SMN2-SPLICING TARGETING THERAPY
More informationRoche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics.
Media Release PRIME designation granted by European Medicines Agency for Roche s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the
More informationTreatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase, open-label, dose-escalation study Richard S Finkel, Claudia A Chiriboga, Jiri Vajsar, John W Day, Jacqueline Montes, Darryl
More informationCURRICULUM VITAE. Phone: (614) Lane Road Department of Pathology MR5 Building, Room Charlottesville, VA 22903
CURRICULUM VITAE NAME: AFFILIATION: CITIZENSHIP: HOME ADDRESS: OFFICE ADDRESS: Jordan T. Gladman Postdoctoral Research Associate The University of Virginia Charlottesville, Virginia 22908 Citizen of U.S.A.
More informationUpdate in Neuromuscular Disorders Tuesday 5- Friday 8 May Clinical Neuroscience Lecture Theatre at 33 Queen Square, London WC1N 3BG PROGRAMME
Update in Neuromuscular Disorders Tuesday 5- Friday 8 May 2015 Clinical Neuroscience Lecture Theatre at 33 Queen Square, London WC1N 3BG Day 1 Tuesday 5 May PROGRAMME 10:00 10:30 Registration* and coffee
More informationStudying Alternative Splicing
Studying Alternative Splicing Meelis Kull PhD student in the University of Tartu supervisor: Jaak Vilo CS Theory Days Rõuge 27 Overview Alternative splicing Its biological function Studying splicing Technology
More informationSMA Treatments and Clinical Trials. Kenneth Hobby, President Mary Schroth, MD, Chief Medical Officer Jill Jarecki, PhD, Chief Scientific Officer
SMA Treatments and Clinical Trials Kenneth Hobby, President Mary Schroth, MD, Chief Medical Officer Jill Jarecki, PhD, Chief Scientific Officer Agenda Introduction Kenneth Hobby, President Spinraza Update
More informationMuscular Dystrophy. Biol 405 Molecular Medicine
Muscular Dystrophy Biol 405 Molecular Medicine Duchenne muscular dystrophy Duchenne muscular dystrophy is a neuromuscular disease that occurs in ~ 1/3,500 male births. The disease causes developmental
More informationClinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327
Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More information(SMN1), which is found in the lower part of the spinal cord. 1 There are several different types of
SMA and the role of the Survival Motor Neuron 1 Gene Jacqueline Seals Copyright May, 2015, Jacqueline Seals and Koni Stone Spinal muscular atrophy (SMA) is one of the leading causes of infant mortality.
More informationPathological impact of SMN2 mis splicing in adult SMA mice
OPEN ACCESS TRANSPARENT PROCESS Post developmental pathology in SMA Pathological impact of SMN2 mis splicing in adult SMA mice Kentaro Sahashi 1, Karen K. Y. Ling 2, Yimin Hua 1, John Erby Wilkinson 3,
More informationthey have one or two SMN1 genes. In most places, this test will only be done when an individual is an adult or of child bearing age.
Families of Spinal Muscular Atrophy Transcript of Chat Live with an Expert December 1, 2004 Topic: Genetics and SMA Our expert is Louise Simard, PhD, and SMA researcher at Montreal s Saint Justine Hospital.
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNew Drug Evaluation: Nusinersen Injection, Intrathecal
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationSALSA MLPA KIT P060-B2 SMA
SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the
More informationNusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study
21 st International Congress of the World Muscle Society -8 October, 2016 Granada, Spain Nusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From
More informationOligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy
The Journal of Neuroscience, June 17, 2009 29(24):7633 7638 7633 Brief Communications Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of
More informationSMA Treatment Access and Clinical Trials Webinar. February 15, 2018
SMA Treatment Access and Clinical Trials Webinar February 15, 2018 Treatment Access Update Current Dosing Metrics December 2017: ~1,900 patients been dosed in US Including those in extension trials and
More informationMRC-Holland MLPA. Description version 19;
SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL
More informationTREAT-NMD Partner Newsletter No th June 2007 and Club of Interest Newsletter No. 11
TREAT-NMD Partner Newsletter No. 17 29 th June 2007 and Club of Interest Newsletter No. 11 Welcome to the eleventh newsletter for the TREAT-NMD Club of Interest. This week s edition features a report on
More informationLetter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
TEMPLATE Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Date: [Insert Name of Medical Director] RE: Patient Name [ ] [Insurance Company] Policy Number [ ] [Address]
More informationA Quick Guide to the. I507del. Mutation CFTR SCIENCE
A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum
More informationNEW HORIZONS IN TREATING SMA. Dr. Huda Mussaffi Schneider Children s Medical Center of Israel
NEW HORIZONS IN TREATING SMA Dr. Huda Mussaffi Schneider Children s Medical Center of Israel WHAT IS SMA? Rare and debilitating autosomal recessive neuromuscular disease characterized by degeneration of
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Advances in therapy for spinal muscular atrophy: promises and challenges Citation for published version: Groen, E, Talbot, K & Gillingwater, T 2018, 'Advances in therapy for
More informationDOSAGE FORMS AND STRENGTHS Injection: 12 mg/5 ml (2.4 mg/ml) in a single-dose vial (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPINRAZA safely and effectively. See full prescribing information for SPINRAZA. SPINRAZA (nusinersen)
More informationGene therapy and genome editing technologies for the study and potential treatment of :
WORKSHOP ON GENOME EDITING Gene therapy and genome editing technologies for the study and potential treatment of : Duchenne Muscular Dystrophy by Dr France Piétri-Rouxel, Institut de Myologie Centre de
More informationMechanism of splicing
Outline of Splicing Mechanism of splicing Em visualization of precursor-spliced mrna in an R loop Kinetics of in vitro splicing Analysis of the splice lariat Lariat Branch Site Splice site sequence requirements
More informationBio 111 Study Guide Chapter 17 From Gene to Protein
Bio 111 Study Guide Chapter 17 From Gene to Protein BEFORE CLASS: Reading: Read the introduction on p. 333, skip the beginning of Concept 17.1 from p. 334 to the bottom of the first column on p. 336, and
More informationAmbulant & non ambulant (Types 2 & 3) Spinal Muscular Atrophy
Ambulant & non ambulant (Types 2 & 3) Spinal Muscular Atrophy Mário Miguel Rosa, MD, PhD SAWP, CNSWP (EMA) FMUL, INFARMED Lisbon - Portugal SMA EMA workshop An agency of the European Union Content Relevant
More informationUsing Biomarkers to Increase the Efficiency of Early Stage Drug Development
Using Biomarkers to Increase the Efficiency of Early Stage Drug Development Personal consulting compensation received from Cytokinetics, Biogen, MT Pharma, Lilly, Karyopharm, Denali Goals of Talk Describe
More informationMeasurement of SMN protein in Blood samples Biomarker test for SMA. Thesis. By Hongyang Pi Chemical and Biomolecular Engineering
Measurement of SMN protein in Blood samples Biomarker test for SMA Thesis Presented in Partial Fulfillment of the Requirements for the Honors Degree Bachelor of Science in the undergraduate college of
More informationA Quick Guide to the G A. Mutation CFTR SCIENCE
A Quick Guide to the 1717-1G A Mutation FR SIENE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of FR activity is the underlying cause of cystic fibrosis (F) 1 Spectrum of Phenotypes
More informationLIHR La ricerca sulle malattie rare e le prospettive di cura per la malattia di Huntington. Neuroscience, the Future is Bright
LIHR La ricerca sulle malattie rare e le prospettive di cura per la malattia di Huntington Neuroscience, the Future is Bright Mauro Patroncini, MD Pipeline Product Strategy Leader Luisa De Stefano Head
More informationMetabolic changes in SBMA. Andy Lieberman University of Michigan Medical School
Metabolic changes in SBMA Andy Lieberman University of Michigan Medical School Research funding: NIH, MDA, APMRF Disclosures Scientific advisory boards: KDA, NNPDF Industry collaborations: Ionis Pharmaceuticals
More informationFinancial Disclosures
October 1, 2014 Nonclinical Development of Enzyme Replacement Therapies for Severely Affected Patients of Orphan Diseases: Assessment of Animal Model and Normal Animal Toxicology Data Charles A. O Neill,
More informationMutation specific therapies
Taken from www.dmd.nl/gt. Used with permission Mutation specific therapies Introduction Two therapies for Duchenne patients are currently being tested in clinical trials, which are applicable only to patients
More informationNIH Public Access Author Manuscript J Child Neurol. Author manuscript; available in PMC 2012 January 17.
NIH Public Access Author Manuscript Published in final edited form as: J Child Neurol. 2007 August ; 22(8): 957 966. doi:10.1177/0883073807305665. Perspectives on Clinical Trials in Spinal Muscular Atrophy
More informationTREAT-NMD Conference 2013
TREAT-NMD Conference 2013 Utility of patient registries for clinical care and post-marketing surveillance Jan Verschuuren Leiden University Medical Centre Newcastle 30 October 1 November 2013 2 Improving
More informationProsensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, Hans Schikan, CEO
Prosensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, 2014 Hans Schikan, CEO Forward-Looking Statements This presentation may contain statements that constitute forward-looking
More informationExon skipping in a DCM mouse model mimicking a human mutation in titin
Exon skipping in a DCM mouse model mimicking a human mutation in titin Dr. Michael Gramlich Department of Cardiology, University of Tuebingen, Germany I do not have a financial interest/arrangement or
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 11.28.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationDisclosures Arthur Burghes. SAB AveXis. Performed studies funded by AveXis. Consulted for Novartis
Disclosures Arthur Burghes SAB AveXis Performed studies funded by AveXis Consulted for Novartis Type of Biomarker Prognostic Disease Progression Predictive Pharmacodynamic Surrogate Endpoint Definition
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationAdvancing Mitochondrial Medicine. Thomas Meier, PhD CEO
Advancing Mitochondrial Medicine Thomas Meier, PhD CEO Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationDiagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1
Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1 17 th April 2018 Adnan Manzur Consultant Paediatric Neurologist Dubowitz Neuromuscular Centre, GOSH & ICH,
More informationNext generation therapeutics and personalised care for Epilepsy
RCSI Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Next generation therapeutics and personalised care for Epilepsy Professor David C. Henshall, Ph.D. Department of Physiology
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Highly Specialised Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Highly Specialised Technology Evaluation Drisapersen for treating Duchenne muscular Draft scope (pre-referral) Draft remit/evaluation objective
More informationGene Medicines for Exon Skipping
Gene Medicines for Exon Skipping Steve Wilton, Penny Harding and Sue Fletcher Experimental Molecular Medicine Group & the NDC Genotyping Facility Centre for Neuromuscular and Neurological Disorders University
More informationExon skipping will change the fast Duchenne into the much slower Becker dystrophy
Duchenne Muscular Dystrophy Exon skipping will change the fast Duchenne into the much slower Becker dystrophy An interview with Professor Stephen D. Wilton Professor Wilton is Head of the Experimental
More informationUpdate in Neuromuscular Disorders Monday 16 th Friday 20 th June 2008 Wolfson Lecture Theatre, NHNN, Queen Square, London WC1N 3BG
Update in Neuromuscular Disorders Monday 16 th Friday 20 th June 2008 Wolfson Lecture Theatre, NHNN, Queen Square, London WC1N 3BG Day 1 Monday 16 th June 2008 Muscular dystrophies in childhood 09:00 09:30
More informationChapter 2. Investigation into mir-346 Regulation of the nachr α5 Subunit
15 Chapter 2 Investigation into mir-346 Regulation of the nachr α5 Subunit MicroRNA s (mirnas) are small (< 25 base pairs), single stranded, non-coding RNAs that regulate gene expression at the post transcriptional
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationAction Duchenne Conference London, 2 nd -4 th November 2007
Action Duchenne Conference London, 2 nd -4 th November 2007 In November 2007 I attended the Action Duchenne annual conference in London. It was a very full agenda, with a range of presentations from internationally
More informationAssociation of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4
jnnp-2016-314292 1 - SUPPLEMENTARY FILE - Methods and additional data on clinical characteristics and motor development Association of motor milestones and SMN2 copy and outcome in spinal muscular atrophy
More informationSpinal Muscular Atrophy Clinical Research Center
Spinal Muscular Atrophy Clinical Research Center F A L L 2 0 1 0 C O L U M B I A U N I V E R S I T Y S M A C L I N I C A L R E S E A C H C E N T E R INTERDISCIPLINARY RESEARCH TEAM Director Darryl De Vivo,
More informationClinical Policy Title: Spinraza
Clinical Policy Title: Spinraza Clinical Policy Number: 02.02.03 Effective Date: July 1, 2018 Initial Review Date: May 19, 2017 Most Recent Review Date: June 5, 2018 Next Review Date: June 2019 Related
More informationMolecular Biology (BIOL 4320) Exam #2 May 3, 2004
Molecular Biology (BIOL 4320) Exam #2 May 3, 2004 Name SS# This exam is worth a total of 100 points. The number of points each question is worth is shown in parentheses after the question number. Good
More informationTREAT-NMD Neuromuscular Network
TREAT-NMD Neuromuscular Network 16 th November 2007 Newsletter No. 21 Welcome to the latest newsletter from the TREAT-NMD network. This edition features a meeting report from last week s patient registry
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationRelated Policies None
Medical Policy MP 5.01.28 BCBSA Ref. Policy: 5.01.28 Last Review: 04/30/2018 Effective Date: 07/30/2018 Section: Prescription Drug Related Policies None DISCLAIMER Our medical policies are designed for
More informationThe clinical landscape for SMA in a new therapeutic era
OPEN Gene Therapy (2017) 24, 529 533 www.nature.com/gt REVIEW The clinical landscape for SMA in a new therapeutic era K Talbot 1,4 and EF Tizzano 2,3,4 Despite significant advances in basic research, the
More informationSpinal muscular atrophy 5Q Treatment with nusinersen
GUIDELINES IN FOCUS Spinal muscular atrophy 5Q Treatment with nusinersen Author: Brazilian Medical Association Participants: Antonio Silvinato; Wanderley M Bernardo Final version: May 5, 2018 1. Brazilian
More informationFaculty Disclosure. Sanjay P. Singh, MD, FAAN. Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion
Faculty Disclosure Sanjay P. Singh, MD, FAAN Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion however, no conflict of interest exists for this conference.
More informationInterim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants With Spinal Muscular Atrophy
American Academy of Neurology 2017 69th Annual Meeting April 22 28, 2017 Boston, MA Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants With
More informationCOMPASS. A Publication Dedicated to Research Updates SUMMER Cure SMA Awards 10 New Grants in Basic Research
COMPASS A Publication Dedicated to Research Updates Cure SMA Awards 10 New Grants in Basic Research In this issue of Compass, we are proud to announce over $1.03 million in new funding. Basic Research
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Nusinersen Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 5 References... 5 Effective Date... 10/15/2017 Next
More informationRVC OPEN ACCESS REPOSITORY COPYRIGHT NOTICE
RVC OPEN ACCESS REPOSITORY COPYRIGHT NOTICE This is the peer reviewed version of the following article: Aartsma-Rus, A and Ferlini, A and Goemans, N and Pasmooij, A M G and Wells, D J and Bushby, K and
More informationBarun Kumar et al., Asian Journal of Pharmaceutical Technology & Innovation, 03 (12); 2015; 57-68
Asian Journal of Pharmaceutical Technology & Innovation ISSN: 2347-8810 Review Article Received on: 31-03-2015 Accepted on: 17-04-2015 Published on: 15-06-2015 Corresponding Author: * Barun Kumar, M.S.
More informationNusinersen Use in Spinal Muscular Atrophy
Nusinersen Use in Spinal Muscular Atrophy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Slide 1 Evidence in Focus Endorsement and
More informationREGULATION OF SMN EXPRESSION BY DcpS INHIBITION IN SPINAL MUSCULAR ATROPHY. Cinsley Gentillon
REGULATION OF SMN EXPRESSION BY DcpS INHIBITION IN SPINAL MUSCULAR ATROPHY by Cinsley Gentillon A thesis submitted to the Faculty of the University of Delaware in partial fulfillment of the requirements
More informationChapter 7. Discussion and impact
Chapter 7 Discussion and impact 225 Affective pathology is a complex construct which encompasses a pathological disturbance in primary emotions, rapidly shifting from neutral to intense perception, associated
More informationAdvances in Progressive MS Research. Nicholas LaRocca, PhD
Advances in Progressive MS Research Nicholas LaRocca, PhD Overview 1. What is progressive MS? 2. Key advances in progressive MS research 3. What is your Society doing to find solutions for people living
More informationJoint Programming in Neurodegenerative Disease Research (JPND)
Joint Programming in Neurodegenerative Disease Research (JPND) Building Alliances and Collaborations Prof. Philippe Amouyel, MD, PhD JPND Chair France Disclosure CEO of Fondation Plan Alzheimer Conference
More informationHow Clinical Trials Work
A Guide to: How Clinical Trials Work Clinical trials are rigorously controlled tests designed to examine the safety and / or effectiveness of medicines, devices, treatments, or preventive measures in humans.
More information